A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

Phase 1/2 Withdrawn University of Florida Teva Pharmaceutical Industries, Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and establish the maximum tolerated dose (MTD) of omacetaxine in combination with azacitidine and G-CSF in patients with relapsed and/or refractory MDS.

Timeline

Start: 2016-08
Primary completion: 2018-12
Completion: 2018-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Omacetaxine	Unknown	—	Subcutaneous
Background	Azacitidine	Other / unclassified	50 mg/m2	Subcutaneous
Background	G-CSF	Unknown	5 ug/kg	Subcutaneous

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

Summary

Timeline

Drugs

Indications